StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report released on Monday morning.
Several other brokerages have also issued reports on CRSP. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Barclays dropped their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Chardan Capital reiterated a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $77.93.
Check Out Our Latest Research Report on CRSP
CRISPR Therapeutics Price Performance
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the business posted ($1.41) earnings per share. Analysts expect that CRISPR Therapeutics will post -5.13 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 1.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,382 shares of company stock valued at $2,744,179 over the last 90 days. Company insiders own 4.10% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in CRSP. Larson Financial Group LLC lifted its holdings in CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in CRISPR Therapeutics in the 2nd quarter worth $35,000. Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics in the 3rd quarter worth $40,000. Darwin Wealth Management LLC bought a new stake in CRISPR Therapeutics during the third quarter valued at about $43,000. Finally, Denver PWM LLC purchased a new position in shares of CRISPR Therapeutics in the second quarter valued at about $45,000. 69.20% of the stock is owned by hedge funds and other institutional investors.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Articles
- Five stocks we like better than CRISPR Therapeutics
- Compound Interest and Why It Matters When Investing
- Work and Play: Investing in the Rise of Bleisure Travel
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- 3 Fintech Stocks With Good 2021 Prospects
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.